Skip to main content
  • NIPER SAS Nagar student gets Rs. 27.8 lakh annual package

    NIPER SAS Nagar has informed that the highest annual package offered to a student is Rs. 27.8 lakh. Many companies conducted campus interviews for the M.Pharm or Masters students of the batch 2020-22.

  • Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics

    Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction. A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

  • Novartis starts new manufacturing plant in Mumbai

    Novartis starts a new plant in Mumbai to make generic cancer drugs. It said that to reinforce our commitment to improving and extending people’s lives, Sandoz Technical Operations, a Novartis division, inaugurated its manufacturing plant for medicines and therapies at Kalwe in Mumbai today.

    The plant, which marks a new chapter for Sandoz, will further strengthen the company’s operations in India to support growing healthcare needs globally.

  • Dr. Reddy's Laboratories announces the acquisition of an injectable product portfolio from Eton Pharma

    Dr. Reddy's Laboratories Ltd.announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals, Inc.

  • U.S. FDA issued Form 483 with six observations at Glenmark Pharma

    U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharma's formulation manufacturing facility based out of Baddi, India between June 13, 2022 and June 22, 2022.

    Harish Kuber, Company Secretary & Compliance Officer, Glenmark Pharma said, The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

  • India not far from joining the league of top 10 in biotech : Prime Minister Narendra Modi

    Inaugurating a two-day biotechnology start-up expo and launching a portal for biotech products at Pragati Maidan here on Thursday, Prime Minister Narendra Modi expressed confidence that India was on the verge of becoming part of the top 10 countries in biotechnology. “India's bio-economy has grown eight times in the last eight years. We have grown from 10 billion dollar to 80 billion dollar. India is not too far off from reaching the league of top-10 countries in Biotech's global ecosystem”, he said.

  • BeiGene announces BRUKINSA (zanubrutinib) Is approved in 50 Markets

    BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has been approved by the Ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry of Public Health in Qatar for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

  • FDA approves Lilly and Incytes OLUMIANT (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

    Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.  The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4-mg/day.

  • Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL

    Novartis announced long-term results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months.

  • Pharma forum express concern over online sale of medicine and hike in medicine prices

    The Joint Action Forum of Pharmaceutical Organisations expressed concern to take note on the development of sale of medicines through online mode as well as enhancement of medicine prices in recent periods.

    The Joint Action Forum of Pharmaceutical Organisations (JAFPO) comprising the Chemists & Druggists Association of Assam, Centre of Medical & sales Representative union, North East Region, Association of Advanced Pharmacy Practitioners & Assam Pharmaceutical Association.

Subscribe to Industry News

Search this website